| Resum: |
Immune checkpoint inhibitors (ICIs) are increasingly used to treat various cancers. Their use may result in immune-related adverse events, including psoriasis. When managing psoriasis, induced or exacerbated by an ICI, there are concerns regarding immunosuppression from systemic agents for the treatment of psoriasis (saPs) and the potential impact on ICI efficacy. No direct, high-level evidence exists to address these concerns. To address clinically relevant questions regarding the management of ICI-mediated psoriasis (ICI-Ps) with saPs. We convened a multidisciplinary panel of 15 international specialists in dermatology, oncology, immunology, and rheumatology. A Delphi process defined clinical concerns related to the systemic treatment of ICI-Ps, focusing on the potential of saPs to impact ICI effectiveness. The saPs considered included biologics targeting tumour necrosis factor, interleukin (IL)-17, IL-12/23 and IL-23, traditional systemic therapies (cyclosporine, methotrexate), small molecules targeting phosphodiesterase-4 or tyrosine kinase 2, systemic retinoids (acitretin), and systemic corticosteroids. A systematic review of the literature was supplemented with evidence supporting an inference-based methodology to derive conclusions on the use of systemic therapies in patients with ICI-Ps. The specialist panel rated the strength of the conclusions using a probabilistic scale. After reviewing the totality of direct and indirect evidence, we drafted inference-based conclusions and ascribed a level of support, focusing on the potential impact of saPs on ICI efficacy. This work provides a structured framework informing healthcare professional and patient discussions on the risks and benefits of using saPs in patients with cancer who experience ICI-Ps. Although there is no direct evidence, we support the following conclusions: saPs may be used to treat ICI-Ps without an appreciable loss of ICI effectiveness. Generally, it is not necessary to interrupt ICI therapy. When available, non-steroid saPs are preferred over systemic corticosteroids for the treatment of psoriasis. When managing psoriasis, induced or exacerbated by ICI therapy for cancer, there are concerns regarding immunosuppression from systemic agents for the treatment of psoriasis and the potential impact on ICI efficacy. No direct, high-level evidence exists to address these concerns. ICI, immune checkpoint inhibitor; ICI-Ps, ICI-mediated psoriasis; IL, interleukin; PDE-4, phosphodiesterase-4; saPs, systemic agents for the treatment of psoriasis; TNF, tumour necrosis factor; TYK2, tyrosine kinase 2. |
visitant ::
identificació
(University of Toronto)
